<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03874429</url>
  </required_header>
  <id_info>
    <org_study_id>LT2259-001</org_study_id>
    <nct_id>NCT03874429</nct_id>
  </id_info>
  <brief_title>Efficacy of T2259 in DED</brief_title>
  <official_title>Comparison of the Performance and Safety of T2259 Versus Vismed Multi in Dry Eye Patients With Superficial Keratitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoires Thea</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoires Thea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the performance and safety of T2259 versus Vismed
      Multi in dry eye patients with superficial keratitis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 5, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>evaluation of ocular staining grade</measure>
    <time_frame>Day 35</time_frame>
    <description>Oxford score</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>T2259</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 drop in each eye 2 to 4 times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vismed Multi</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 drop in each eye 2 to 4 times daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>T2259</intervention_name>
    <description>HA and Trealose</description>
    <arm_group_label>T2259</arm_group_label>
    <other_name>HA and Trealose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vismed multi</intervention_name>
    <description>HA</description>
    <arm_group_label>Vismed Multi</arm_group_label>
    <other_name>HA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed and dated informed consent

          -  Male or female aged from ≥ 18 years old

          -  Known Dry Eye Syndrome requiring artificial tears within the last 3 months

        Exclusion Criteria:

          -  Far best-corrected visual acuity≤2/10

          -  Severe Blepharitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marielle ESTRADE</last_name>
    <phone>0473989539</phone>
    <email>marielle.estrade@theapharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lydia Bresson</last_name>
    <phone>0473989507</phone>
    <email>lydia.bresson@theapharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>C.H.N.O des XV-XX</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe BAUDOUIN, Professor</last_name>
      <phone>00.33.(0)1.40.02.16.18</phone>
      <email>baudouin@quinze-vingts.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe BAUDOUIN, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 12, 2019</study_first_submitted>
  <study_first_submitted_qc>March 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2019</study_first_posted>
  <last_update_submitted>August 12, 2019</last_update_submitted>
  <last_update_submitted_qc>August 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

